R&D News | pharmaphorum

News

MSD's tulisokibart was effective in a phase 2 trial in skin disorder hidradenitis suppurativa, but has failed a study in rare lung disorder SSc-ILD.

News

Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.

News

After nearly a decade in the role, Guido Oelkers is stepping down as chief executive of Sobi to take the top job at BioNTech.

News

There are rumours that the first pharma 'mega-merger' for several years – between AstraZeneca and Bristol Myers Squibb – is under discussion.

News

Novo Nordisk's IL-6 inhibitor ziltivekimab has failed the phase 3 ZEUS trial in heart disease, denting its bid to expand into new therapeutic areas.

News

Sleep apnoea drug developer Apnimed has completed its IPO, raising $192m, while Braveheart, Attovia, and Vogenx reveal their terms.